Want to see SE:QLINEA full AI Analyst Report?
Top Page
Q-linea AB
(QLINEA)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr16.50
▼(-10.81% Downside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by weak financial performance—large ongoing losses and heavy cash burn dominate despite low leverage and positive equity. Technicals provide a modest offset with improving medium-term momentum, but valuation remains unattractive/unclear due to negative earnings and no dividend yield.
Positive Factors
Low leverage
Very low leverage reduces the burden of interest and principal obligations, giving Q-linea more financial flexibility while it develops and commercializes its diagnostic platform. Positive equity also provides a stronger current capital base than a highly indebted balance sheet would.
Negative Factors
Large ongoing losses
The scale of current losses shows that Q-linea has not yet established an economically viable cost structure. Persistently negative gross, operating, and net margins can consume capital, restrict reinvestment capacity, and make future profitability dependent on substantial improvement in commercial scale or costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low leverage reduces the burden of interest and principal obligations, giving Q-linea more financial flexibility while it develops and commercializes its diagnostic platform. Positive equity also provides a stronger current capital base than a highly indebted balance sheet would.
Read all positive factors
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr319.29M
Dividend YieldN/A
Average Volume (3M)5.91K
Price to Earnings (P/E)―
Beta (1Y)2.87
Revenue Growth79.55%
EPS Growth90.21%
CountrySE
Employees70
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-13.20
Shares Outstanding18,949,081
10 Day Avg. Volume5,866
30 Day Avg. Volume5,914
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Q-linea AB Business Overview & Revenue Model
Company Description
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antim...
How the Company Makes Money
Q-linea makes money primarily through selling or placing its diagnostic platform(s) and generating recurring revenue from the ongoing use of consumables. Key revenue streams typically include: (1) instrument revenue—sales (or placements under comm...
Q-linea AB Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.86M | 11.10M | 2.36M | 4.44M | 12.79M | 9.34M |
| Gross Profit | -212.69M | -180.02M | -11.11M | 995.00K | -21.38M | -25.03M |
| EBITDA | -137.00M | -160.54M | -195.40M | -210.99M | -252.69M | -218.48M |
| Net Income | -152.62M | -182.49M | -216.87M | -229.37M | -275.77M | -233.18M |
Balance Sheet | ||||||
| Total Assets | 314.77M | 369.67M | 147.99M | 231.98M | 207.39M | 466.63M |
| Cash, Cash Equivalents and Short-Term Investments | 186.77M | 258.11M | 25.66M | 81.89M | 72.62M | 166.03M |
| Total Debt | 11.68M | 5.84M | 151.21M | 20.56M | 20.93M | 79.00K |
| Total Liabilities | 40.09M | 31.66M | 175.45M | 42.34M | 45.76M | 35.84M |
| Stockholders Equity | 274.68M | 338.00M | -27.46M | 189.64M | 161.63M | 430.79M |
Cash Flow | ||||||
| Free Cash Flow | -111.74M | -169.68M | -187.49M | -236.86M | -268.11M | -267.02M |
| Operating Cash Flow | -136.96M | -162.12M | -182.50M | -228.52M | -250.86M | -255.05M |
| Investing Cash Flow | -145.20M | -7.22M | -5.04M | -7.77M | 315.25M | -23.82M |
| Financing Cash Flow | 251.17M | 402.12M | 131.27M | 245.41M | -6.60M | 283.81M |
Q-linea AB Technical Analysis
Negative
18.50
Price Trends
18.14
Negative
17.91
Negative
20.43
Negative
Market Momentum
-0.37
Positive
37.71
Neutral
21.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLINEA, the sentiment is Negative. The current price of 18.5 is above the 20-day moving average (MA) of 17.69, above the 50-day MA of 18.14, and below the 200-day MA of 20.43, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 37.71 is Neutral, neither overbought nor oversold. The STOCH value of 21.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLINEA.
Q-linea AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr3.86B | 29.91 | 14.59% | 1.70% | -1.64% | -14.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr93.98M | -23.31 | -58.52% | 1.06% | -10.60% | 98.81% | |
44 Neutral | kr319.29M | -1.28 | -60.76% | ― | 79.55% | 90.21% | |
44 Neutral | kr459.07M | -4.11 | -37.43% | ― | 27.40% | 26.07% | |
44 Neutral | kr140.71M | -2.05 | -17.52% | ― | -100.00% | 20.94% | |
42 Neutral | kr246.61M | -5.85 | -100.09% | ― | 65.82% | 41.28% |
* Healthcare Sector Average
SE:QLINEA
Q-linea AB
16.85
-9.23
-35.39%
SE:BOUL
Boule Diagnostics AB
2.42
-2.57
-51.50%
SE:CEVI
CellaVision AB
161.80
-14.09
-8.01%
SE:SEZI
Senzime AB
2.92
-2.95
-50.26%
SE:ALZ
Alzinova AB
0.43
-1.30
-74.97%
SE:ACARIX
Acarix AB
0.20
-0.10
-33.78%
Q-linea AB Corporate Events
Q-linea Appoints New CFO to Support Growth in Rapid Infection Diagnostics
Aug 20, 2026
Q-linea AB, a Swedish infection diagnostics specialist listed on Nasdaq Stockholm, develops rapid testing technologies to improve treatment of severe infections, notably through its automated ASTar platform that accelerates antibiotic susceptibili...
Q-linea secures Premier contract to accelerate U.S. rollout of ASTar system
Aug 18, 2026
Q-linea AB, a Swedish infection diagnostics specialist listed on Nasdaq Stockholm, develops rapid testing solutions for infectious diseases with a core focus on rapid antibiotic susceptibility testing. Its flagship ASTar platform is designed to pr...
Q-linea Secures Key U.S. Health System Deal for ASTar Rapid Infection Diagnostics
Aug 10, 2026
Q-linea AB, a Sweden-based infection diagnostics specialist listed on Nasdaq Stockholm, develops rapid Antibiotic Susceptibility Testing solutions that enable faster and more targeted treatment of severe infections such as sepsis. Its core product...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.